ClinicalTrials.gg
AvailableNCT07346105Updated Sep 21, 2026

Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies

An expanded access record providing Orca-T in Hematologic Malignancies, Acute Myeloid Leukemia and Acute Lymphoid Leukemia, sponsored by Orca Biosystems, Inc.. Available at 8 sites in United States. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Orca Biosystems, Inc. · Expanded access

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Treatment IND/protocol
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 823 studies in Hematologic Neoplasms with a site in United States — 182 open to participants now, 278 under way, 12 of them phase 3. Hematologic Neoplasms · United States.

Other kind
3 of 823
none open now
Registered
804th of 823
by date

Among the 823 studies in Hematologic Neoplasms with a site in United States, this one is one of 3 of another kind, and was the 804th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 424 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

182 of the 823 studies in Hematologic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

177 more — sign in →

All 182 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 315 Hematologic Neoplasms studies recruiting now, 211 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 823 studies in Hematologic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study is not designed to test a hypothesis; rather, this study will provide patients with access to Orca-T if the commercial Orca-T product produced for them is deemed out of specification (OOS). Serious adverse events (SAEs) occurring during the safety reporting period (defined as the day the recipient receives the Orca-T HSPC drug product through day +365 after transplantation or until initiation of new anticancer therapy, whichever occurs sooner) will be reported.

03

Conditions studied

  • Hematologic Malignancies
  • Acute Myeloid Leukemia
  • Acute Lymphoid Leukemia
  • Myelodysplastic Syndrome
  • Mixed Phenotype Acute Leukemia

Keywords

  • Hematopoietic stem cell transplantation
  • Acute leukemia
  • Myelodysplastic syndromes
  • Matched related donor
  • Matched unrelated donor
  • Myelodysplastic syndrome
  • TREGZI
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Recipients in this EAP must meet all of the following criteria:

  1. Commercial Orca-T was prescribed to the patient by their treating physician.
  2. The final manufactured Orca-T does not meet the commercial release specifications or is delivered past expiry.
  3. The final manufactured Orca-T is acceptable per joint assessment by Orca Bio and the treating physician, taking into account Orca Bio's release criteria.
  4. Remanufacturing (ie, repeat leukapheresis and manufacturing) is not clinically appropriate per the treating physician's assessment.
  5. Recipient must be deemed medically fit and stable to receive Orca-T infusions per the treating physician's evaluation.

Exclusion criteria

Exclusion Criteria:

Recipients with any medical condition identified by the treating physician that may impact the safety or outcomes of the recipient in relation to treatment with Orca-T will not be eligible.

05

Access details

Study type
Expanded access
Access type
Treatment IND/protocol

Available treatment

  • BiologicalOrca-T

    Orca-T that does not meet commercial release specifications

06

Where to request access

8 of 8 sites recruiting
  • UCLA Department of Medicine - Hematology/Oncology
    Los Angeles, California 90095, United States
    Available
    • Caspian Oliai, MD · Contact
  • Stanford Cancer Institute
    Palo Alto, California 94304, United States
    Available
    • Andrew Rezvani, MD · Contact
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
    Available
    • Nelli Benjanyan, MD · Contact
  • The University of Kansas Hospital
    Kansas City, Kansas 66160, United States
    Available
    • Joseph McGuirk, DO, FACP · Contact
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Available
    • Richard Newcomb, MD · Contact
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Available
    • Roni Tamari, MD, MS · Contact
  • The Ohio State University Wexner Medical Center - James Cancer Hospital
    Columbus, Ohio 43210, United States
    Available
    • Sarah Wall, MD, MPH · Contact
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
    Available
    • Jana Reynolds, MD · Contact
07

References and documents

Publications

  • Meyer EH, Salhotra A, Gandhi AP, Pantin J, Patel SS, Hoeg RT, Gomez-Arteaga A, Faramand R, Tamari R, Waller EK, Kosuri S, Jimenez Jimenez AM, Holter-Chakrabarty J, Dholaria B, Chen YB, Hamilton BK, Magenau J, Eghtedar A, Murray JM, Pavlova A, Fernhoff NB, McClellan JS, Killian MS, Li A, Negrin RS, Oliai C. Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial. Blood. 2026 Mar 12;147(11):1168-1177. doi: 10.1182/blood.2025031313. PubMed 41385341 ↗
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07346105
Lead sponsor
Orca Biosystems, Inc.
Responsible party
Sponsor
First posted
Jan 16, 2026
Last update
Sep 21, 2026

Study contacts

James S. McClellan, MD, PhD
Contact
info@orcabio.com
530-414-9723
Anna Pavlova, MD, PhD
Contact
info@orcabio.com
530-414-9723
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

Contact the provider

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion